Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Type and doses of oral anticoagulants and adherence to anticoagulant treatment in elderly patients with atrial fibrillation: the ESPARTA study.
Mostaza JM, Suárez Fernández C, Castilla Guerra L, Suriñach JM, Tamarit JJ, Diaz Diaz JL, García Polo I, Santamaria EF, Fidalgo Fernández MA, de la Guerra Acebal C, Dávila Ramos MF, Ràfols C. Mostaza JM, et al. Among authors: rafols c. J Comp Eff Res. 2018 Mar;7(3):223-232. doi: 10.2217/cer-2017-0034. Epub 2018 Feb 21. J Comp Eff Res. 2018. PMID: 29465254 Free article.
[Validation of satisfaction questionnaire ACTS in outpatients with atrial fibrillation treated with oral anticoagulants in Spain. ALADIN Study].
Suárez C, Pose A, Montero-Pérez-Barquero M, Roquer J, Gállego J, Ràfols C, Cazorla D, Vivancos J; en representación del Grupo de Trabajo Comité Científico Estudio ALADIN. Suárez C, et al. Among authors: rafols c. Med Clin (Barc). 2016 Sep 2;147(5):192-198. doi: 10.1016/j.medcli.2016.05.024. Epub 2016 Jul 14. Med Clin (Barc). 2016. PMID: 27423653 Spanish.
Benefits of Emergency Departments' Contribution to Stroke Prophylaxis in Atrial Fibrillation: The EMERG-AF Study (Emergency Department Stroke Prophylaxis and Guidelines Implementation in Atrial Fibrillation).
Coll-Vinent B, Martín A, Sánchez J, Tamargo J, Suero C, Malagón F, Varona M, Cancio M, Sánchez S, Carbajosa J, Ríos J, Casanovas G, Ràfols C, Del Arco C; EMERG-AF Investigators. Coll-Vinent B, et al. Among authors: rafols c. Stroke. 2017 May;48(5):1344-1352. doi: 10.1161/STROKEAHA.116.014855. Epub 2017 Apr 7. Stroke. 2017. PMID: 28389612 Free PMC article.
Adherence to recommendations of the Therapeutic Positioning Report about treatment with oral anticoagulants in elderly patients with atrial fibrillation. The ESPARTA study.
Suárez Fernández C, Mostaza JM, Castilla Guerra L, Cantero Hinojosa J, Suriñach JM, Acosta de Bilbao F, Tamarit JJ, Diaz Diaz JL, Hernandez JL, Cazorla D, Ràfols C; en nombre de los Investigadores del Estudio ESPARTA. Suárez Fernández C, et al. Among authors: rafols c. Med Clin (Barc). 2018 Jul 13;151(1):8-15. doi: 10.1016/j.medcli.2017.07.025. Epub 2017 Oct 6. Med Clin (Barc). 2018. PMID: 28992980 English, Spanish.
Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study.
López-Gálvez R, Rivera-Caravaca JM, Anguita Sánchez M, Sanmartín Fernández M, Rafols C, Pérez-Cabeza AI, Barón Esquivias G, Lekuona Goya I, Vázquez Rodríguez JM, Cosín Sales J, Arribas Ynsaurriaga F, Barrios V, Freixa-Pamias R, Marín F. López-Gálvez R, et al. Among authors: rafols c. Eur J Clin Invest. 2022 Sep;52(9):e13788. doi: 10.1111/eci.13788. Epub 2022 Apr 14. Eur J Clin Invest. 2022. PMID: 35395094
Adverse Clinical Outcomes and Associated Predictors in Rivaroxaban-Treated Atrial Fibrillation Patients With Renal Impairment.
Rivera-Caravaca JM, Anguita Sanchez M, Sanmartín Fernández M, Rafols C, Barón-Esquivias G, Arribas Ynsaurriaga F, Freixa-Pamias R, Lekuona Goya I, Vázquez Rodríguez JM, Pérez-Cabeza AI, Cosín-Sales J, Ureña Montilla I, Álvarez-Vieitez Blanco A, Marín F. Rivera-Caravaca JM, et al. Among authors: rafols c. Am J Cardiol. 2023 Sep 15;203:122-127. doi: 10.1016/j.amjcard.2023.06.105. Epub 2023 Jul 22. Am J Cardiol. 2023. PMID: 37487406 Free article.
Factors associated with disease progression in patients with atrial fibrillation and heart failure anticoagulated with rivaroxaban.
Manito N, Cepeda-Rodrigo JM, Farré N, Castillo Orive M, Galve E, Jiménez-Candil J, García-Pinilla JM, López Sánchez ES, Rafols C, Gómez Doblas JJ. Manito N, et al. Among authors: rafols c. Clin Cardiol. 2024 Feb;47(2):e24189. doi: 10.1002/clc.24189. Epub 2023 Nov 29. Clin Cardiol. 2024. PMID: 38018889 Free PMC article.
97 results